News

First Commercial Cases Successfully Completed CHARLOTTE, N.C., March 27, 2025 /PRNewswire/ — Vasorum USA, Inc, a privately held, commercial-stage medical device company dedicated to redefining vascular closure, today announced U.S. Food and Drug Administration (FDA) approval of the Celt ACD® PLUS System, featuring Blood Signal technology. This next-generation device enhances the proven Celt ACD® platform by providing physicians with a visual indicator for precise placement and closure, particularly beneficial in cases where ultrasound imaging is not available. The Celt ACD® PLUS is an innovative small-bore closure device available in 5F, 6F, and 7F sizes, designed for rapid arterial puncture closure following percutaneous catheter-based vascular procedures. Its novel mechanism of action reduces major vascular closure complications such as bleeding,… View Article

BGF – Ireland’s largest growth capital investor – has completed a €6 million equity investment in Vasorum Limited. Vasorum is a Dublin based high-growth medical device business specialising in sophisticated devices used to close arterial punctures in vascular, cardiology, radiology and neuro-radiology procedures. BGF invests in minority positions in growing businesses and aims to support and facilitate the growth plans of founders and owners. BGF in Ireland is supported by the Ireland Strategic Investment Fund (ISIF) and the main Irish banks. Based in Dublin, Vasorum is led by Founder and CEO, Dr. Jim Coleman, and former CR Bard senior executive and serial entrepreneur Chas Taylor. Vasorum developed and markets the CELT® Arterial Closure… View Article

DUBLIN, Ireland, September 12, 2017 /PRNewswire/ —Vasorum Ltd, following FDA approval of its PMA supplement, the developer and manufacturer of the novel Celt ACD vascular closure device has added a 7F sized Celt ACD device to its Celt ACD 6F and Celt ACD 5F size range in the USA. Celt ACD is indicated for arterial puncture closure in both diagnostic and interventional cardiology and radiology patients. Celt ACD offers excellent time to hemostasis in a wide variety of clinical situations. The second generation Celt ACD devices now available in both the USA and Europe have a new improved delivery system which has been designed to enhance the user experience during deployment. The… View Article

DUBLIN, July 21, 2016 /PRNewswire/ —Vasorum Ltd. The developer and manufacturer of the novel Celt ACD vascular closure device has received approval of its PMA application from the US Food and Drug Administration (FDA). Celt ACD, which previously received CE mark and is sold in Europe, is indicated for arterial puncture closure in both diagnostic and anticoagulated percutaneous interventional cardiology and radiology patients. Celt ACD offers excellent time to hemostasis in a wide variety of clinical situations. A randomized controlled clinical trial which recruited 207 interventional cardiology procedure patients was carried out in four International Cardiology Centres across US and Europe. The trial’s Principal Investigator was Dr. Shing-Chiu Wong, Director of Cardiac… View Article